Foghorn Therapeutics falls on pausing enrollment in cancer study

Foghorn Therapeutics

24/04/2023 13:15

** Shares of biopharma co Foghorn Therapeutics  FHTX.O  fall
18.1% to $5.50 in premarket trading
    ** Co pauses enrollment in early-stage study of its
experimental cancer drug, FHD-609, due to safety concerns
    ** At the second-highest dose of study, a serious
complication related to the heart was seen in a patient,
prompting the pause
    ** Patients in affected cohort were dose-reduced and
additional safety measures have been discussed with and provided
to study investigators - FHTX
    ** Co says FDA has put the study on partial clinical hold in
U.S.
    ** FDA has allowed patients currently enrolled and
benefiting from therapy to continue dosing and to remain on the
drug
    ** FHTX is not planning to pursue a dose expansion study
independently
    ** Up to last close, stock had risen 5.3% so far this year

 (Reporting by Ashwini Raj in Bengaluru)
 ((Ashwini.Raj@thomsonreuters.com))